Op-Ed: Drug Advertising is Bad Medicine
Drug advertising is bad medicine: a needed prescription
Op-Ed published September 16, 2003 in The Toronto Star By: Denis Morrice
Although patients should take more responsibility for their health, paid advertising, as extolled by the president of the Canadian Newspaper Association is not the answer.
It is very difficult not to note the bias and conflict of interest of such a column appearing in a
newspaper that would benefit from the increased advertising profits if
the doors were swung wide open on pharmaceutical advertising.
Don't get me wrong, patients deserve information and education, but
there is a difference between this and straight advertising. As
co-chair of the Best Medicines Coalition, an advocacy group
representing millions of Canadians, we believe patients and consumers
should be educated about disease signs, symptoms and different
treatments.
However, this does not mean advertising as currently available in the
U.S. Patients and consumers need to gain information through
discussions with appropriate health-care professionals, through health
and consumer voluntary organizations, through government, including
Health Canada and, finally, through the pharmaceutical companies.
There must be a balance between advertising and education for all pharmaceutical products.
The current legislative renewal of the Health Protection Act must defend and protect patients and
consumers from inappropriate drug advertising; ensure patient-friendly
monographs or other essential information, ensure contact information
is provided and ensure linkages exist with an effective postmarket
surveillance system for patients and health-care providers to access.
What better way to do this than to require that, for every dollar spent
by the industry on advertising pharmaceutical products, another dollar
should be donated by the industry to a national drug education program
or to voluntary health organizations to spend directly on education of
patients/consumers and health-care providers, regarding the
pharmaceutical products being advertised.
This is a debate that must take place with consumers and patients at
the table. Patients need to work with Health Canada, industry and the
for-profit sector to ensure the development of a national consumer and
health-care provider education program.
Denis Morrice